As of November 6, 2026, Cogent Biosciences, Inc. is a publicly traded company (Nasdaq: COGT). The largest holder reporting an active stake on Schedule 13D is Fairmount Funds Management LLC, at 8.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BlackRock (8%), Vanguard (5.08%) (Schedule 13D/A, March 31, 2026).
Is this your company?
About to sign with, pay or invest in Cogent Biosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Cogent Biosciences, Inc. a real, registered company?
- Cogent Biosciences, Inc. files with the SEC under CIK 1622229 (its SEC filings).
- Its shares are listed under the ticker COGT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Cogent Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vanguard (filed 2026-07-31).
Who are Cogent Biosciences, Inc.'s owners and officers?
Cogent Biosciences, Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-13).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Deerfield Mgmt, L.P. | 2.88% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.08% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 8% |
| Schedule 13G/A, 2026-05-14 | Deerfield Mgmt, L.P. | 5.29% |
| Schedule 13D/A, 2026-03-31 | Fairmount Funds Management LLC | 8.6% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Commodore Capital LP | 1.8% |
| Schedule 13G/A, 2026-02-17 | Kynam Capital Management, LP | 4.33% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 7.5% |
| Schedule 13D/A, 2026-01-22 | Fairmount Funds Management LLC | 9.9% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 6.5% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 6.5% |
Questions about who owns Cogent Biosciences, Inc.
Who owns Cogent Biosciences, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Cogent Biosciences, Inc.: Fairmount Funds Management LLC (8.6%, Schedule 13D/A, filed 2026-03-31), Blackrock, Inc. (8%, Schedule 13G/A, filed 2026-07-27) and Vanguard Capital Management (5.08%, Schedule 13G, filed 2026-07-31).
Who are the largest shareholders of Cogent Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Cogent Biosciences, Inc. on this page are Fairmount Funds Management LLC (8.6%), Blackrock, Inc. (8%) and Vanguard Capital Management (5.08%).
When did Fairmount Funds Management LLC buy into Cogent Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2026-01-22, reporting 9.9%; its latest, Schedule 13D/A filed 2026-03-31, reports 8.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Cogent Biosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cogent Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cogent Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Cogent Biosciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Fairmount Funds Management LLC, a director: 5,503,418 shares (3.2% of shares outstanding), held indirectly through Fairmount Healthcare Fund II LP (Form 4, 2026-03-31).
- , the chief executive and president: 657,503 shares (0.38% of shares outstanding), 497,503 held directly and 160,000 indirectly (Form 4, 2026-05-21).
- , the chief commercial officer: 216,650 shares (0.12% of shares outstanding) (Form 4, 2025-12-19).
- , the chief scientific officer: 140,002 shares (0.08% of shares outstanding) (Form 4, 2025-12-30).
- , the chief medical officer: 133,938 shares (0.08% of shares outstanding) (Form 4, 2025-12-30).
Shares outstanding: 173,994,452 as of 2026-11-03, from the company's latest SEC cover page.
How much has Cogent Biosciences, Inc. raised?
No fundraising or offering filing from Cogent Biosciences, Inc. is on file with us.
Keep reading
More on Cogent Biosciences, Inc. and the records around it.
Cogent Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Venrock Healthcare Capital Partners II, L.P. also filed stake reports on 1 other company: DBV TECHNOLOGIES S.A. (Feb 2026)
- TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Abivax SA (Aug 2026), Entrada Therapeutics, Inc. (Aug 2026), Vistagen Therapeutics, Inc. (Aug 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/cogent-biosciences